BECN1 and liver cancer: A single allele loss of Beclin-1 was observed in 40–75% of breast, prostate, and ovarian tumors, and a severely reduced expression of Beclin-1 was observed in prostate, ovarian, colon, brain, breast, and liver cancers (44).